AngioDynamics (NASDAQ:ANGO) Releases Earnings Results, Beats Estimates By $0.04 EPS

AngioDynamics (NASDAQ:ANGO) released its earnings results on Tuesday. The medical instruments supplier reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04, FiscalAI reports. AngioDynamics had a negative return on equity of 4.66% and a negative net margin of 10.01%.The firm had revenue of $86.61 million for the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics updated its FY 2027 guidance to -0.290–0.240 EPS.

AngioDynamics Trading Down 0.2%

Shares of ANGO opened at $12.77 on Tuesday. The firm has a market cap of $527.66 million, a P/E ratio of -17.03 and a beta of 0.34. AngioDynamics has a 12 month low of $8.36 and a 12 month high of $13.99. The stock’s 50 day moving average is $12.03 and its two-hundred day moving average is $11.32.

Analyst Ratings Changes

Several research firms have issued reports on ANGO. Freedom Capital raised shares of AngioDynamics to a “strong-buy” rating in a report on Monday, April 6th. Canaccord Genuity Group lowered their price target on AngioDynamics from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Monday, April 6th. Zacks Research downgraded AngioDynamics from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.67.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. raised its position in AngioDynamics by 9.6% during the first quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier’s stock worth $2,434,000 after acquiring an additional 22,658 shares during the period. Jane Street Group LLC increased its stake in shares of AngioDynamics by 267.1% during the first quarter. Jane Street Group LLC now owns 46,803 shares of the medical instruments supplier’s stock worth $439,000 after purchasing an additional 34,054 shares in the last quarter. Legal & General Group Plc raised its position in shares of AngioDynamics by 279.5% during the 2nd quarter. Legal & General Group Plc now owns 12,353 shares of the medical instruments supplier’s stock worth $123,000 after purchasing an additional 9,098 shares during the last quarter. Rhumbline Advisers raised its position in shares of AngioDynamics by 4.3% during the 2nd quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier’s stock worth $608,000 after purchasing an additional 2,510 shares during the last quarter. Finally, American Century Companies Inc. lifted its stake in AngioDynamics by 15.8% in the 2nd quarter. American Century Companies Inc. now owns 96,808 shares of the medical instruments supplier’s stock valued at $960,000 after buying an additional 13,217 shares in the last quarter. Hedge funds and other institutional investors own 89.43% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.